- Conditions
- Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, LOPD, Lysosomal Storage Diseases, Acid Maltase Deficiency
- Interventions
- Neutralizing Antibody to SPK-3006 capsid
- Diagnostic Test
- Lead sponsor
- Spark Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Orange, California • Kansas City, Kansas + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1609–1632
of 1,713
matching trials from the live ClinicalTrials.gov search.
- Conditions
- MELAS
- Interventions
- IW-6463 Tablets
- Drug
- Lead sponsor
- Tisento Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Tourette's Syndrome
- Interventions
- Ecopipam
- Drug
- Lead sponsor
- Psyadon Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Summit, New Jersey • Manhasset, New York + 1 more
- Conditions
- Huntington Disease
- Interventions
- ACR16, Placebo
- Drug · Other
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • San Diego, California • Littleton, Colorado + 18 more
- Conditions
- Holoprosencephaly, HPE, Developmental Delay Disorders, Brain Disorders
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Charcot-Marie-Tooth Disease, Type IA
- Interventions
- PXT3003
- Drug
- Lead sponsor
- Pharnext S.C.A.
- Other
- Eligibility
- 17 Years to 67 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Gainesville, Florida • Kansas City, Kansas + 6 more
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis
- Interventions
- triamcinolone acetonide (Triesence®)
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Omaha, Nebraska • Cleveland, Ohio
- Conditions
- Type 1 Gaucher Disease
- Interventions
- AT2101
- Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Miramar, Florida
- Conditions
- Sickle Cell Disease, Stroke
- Interventions
- Hydroxyurea, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Months to 54 Months
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Kansas City, Missouri + 2 more
- Conditions
- Gaucher Disease
- Interventions
- Plant cell expressed recombinant glucocerebrosidase (prGCD)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 14
- States / cities
- La Jolla, California • Aurora, Colorado • Coral Springs, Florida + 11 more
- Conditions
- Spina Bifida, Cerebral Palsy
- Interventions
- RL-adaptive application
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Dermatomyositis, Glycogen Storage Disease Type II, Glycogen Storage Disease Type VII, Myositis, Polymyositis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1993 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Alexander Disease
- Interventions
- zilganersen, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
- Conditions
- Arnold Chiari Deformity, Hydrocephalus, Syringomyelia
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Urea Cycle Disorder
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 16 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Down Syndrome, Alzheimer Disease, Obesity
- Interventions
- Diet, Health Education
- Behavioral
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Cryptogenic Stroke
- Interventions
- AMPLATZER PFO Occluder, Standard of Care - Medical Management
- Device · Other
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 52 more
- Conditions
- Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder, ADHD
- Interventions
- Anger control training
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 11 Years to 16 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Neonatal Abstinence Syndrome
- Interventions
- Clonidine, Morphine
- Drug
- Lead sponsor
- Henrietta Bada
- Other
- Eligibility
- 12 Hours to 7 Days
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- zocaglusagene nuzaparvovec
- Genetic
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2035
- U.S. locations
- 3
- States / cities
- Orange, California • Palo Alto, California • Salt Lake City, Utah
- Conditions
- Ornithine Transcarbamylase Deficiency
- Interventions
- No Intervention
- Other
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Low Back Pain
- Interventions
- Tanezumab 20 mg IV, Placebo for naproxen, Tanezumab 10 mg IV, Tanezumab 5 mg IV, Placebo for tanezumab, Naproxen
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 135
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 101 more
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1986 – 2018
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Tuberous Sclerosis Complex, Epilepsy
- Interventions
- Sirolimus, Placebo
- Drug
- Lead sponsor
- Darcy Krueger
- Other
- Eligibility
- 1 Day to 6 Months
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more